Subrata Ghosh
#125,160
Most Influential Person Now
Researcher ORCID ID = 0000-0002-1713-7797
Subrata Ghosh's AcademicInfluence.com Rankings
Subrata Ghoshcomputer-science Degrees
Computer Science
#5215
World Rank
#5509
Historical Rank
Computational Linguistics
#672
World Rank
#684
Historical Rank
Machine Learning
#1297
World Rank
#1317
Historical Rank
Artificial Intelligence
#1531
World Rank
#1560
Historical Rank
Download Badge
Computer Science
Subrata Ghosh's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Subrata Ghosh Influential?
(Suggest an Edit or Addition)Subrata Ghosh's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. (2012) (4135)
- Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies (2017) (2779)
- Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. (2016) (1026)
- Ustekinumab induction and maintenance therapy in refractory Crohn's disease. (2012) (945)
- Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. (2014) (780)
- Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis (2020) (730)
- Natalizumab for active Crohn's disease. (2003) (691)
- Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. (2012) (677)
- Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. (2013) (612)
- European evidence-based Consensus on the management of ulcerative colitis: Current management. (2008) (593)
- Polyunsaturated fatty acids and inflammation (2015) (390)
- NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis (2011) (372)
- Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease (2005) (338)
- Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. (2016) (315)
- Implications of COVID-19 for patients with pre-existing digestive diseases (2020) (311)
- Inflammatory bowel disease: a Canadian burden of illness review. (2012) (272)
- Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. (2007) (264)
- A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. (2014) (252)
- Differentiating Intestinal Tuberculosis From Crohn's Disease: A Diagnostic Challenge (2009) (231)
- Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. (2015) (229)
- The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association (2010) (218)
- Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain (2010) (188)
- Decreasing Colectomy Rates for Ulcerative Colitis: A Population-Based Time Trend Study (2012) (182)
- Fatty acids, eicosanoids and PPAR gamma. (2016) (178)
- Increasing incidence of both juvenile-onset Crohn's disease and ulcerative colitis in Scotland (2001) (177)
- Incidence of juvenile-onset Crohn's disease in Scotland: association with northern latitude and affluence. (2004) (170)
- Characterization of Inflammatory Bowel Disease With Urinary Metabolic Profiling (2009) (167)
- Synergistic enhancement of Toll‐like receptor responses by NOD1 activation (2005) (165)
- Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting (2020) (164)
- Th17 plasticity and its relevance to inflammatory bowel disease. (2017) (164)
- Increased Prevalence of Circulating Novel IL-17 Secreting Foxp3 Expressing CD4+ T Cells and Defective Suppressive Function of Circulating Foxp3+ Regulatory Cells Support Plasticity Between Th17 and Regulatory T Cells in Inflammatory Bowel Disease Patients (2013) (163)
- Postoperative complications and mortality following colectomy for ulcerative colitis. (2011) (162)
- Cumulative Incidence of Second Intestinal Resection in Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Studies (2014) (158)
- Hepatosplenic T cell lymphoma in inflammatory bowel disease (2008) (151)
- Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. (2018) (151)
- The challenge of indication extrapolation for infliximab biosimilars. (2014) (146)
- Successful infliximab treatment for steroid-refractory celiac disease: a case report. (2002) (143)
- Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3 (2014) (137)
- Environment and the inflammatory bowel diseases. (2013) (134)
- Infliximab, Azathioprine, or Infliximab + Azathioprine for Treatment of Moderate to Severe Ulcerative Colitis: The UC Success Trial (2011) (133)
- Vitamin B12 deficiency in untreated celiac disease (2001) (133)
- The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study (2011) (132)
- Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort (2017) (130)
- TRPM8 activation attenuates inflammatory responses in mouse models of colitis (2013) (130)
- Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study (2015) (127)
- Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate‐to‐severe Crohn's disease: an exploratory study (2004) (125)
- Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study (2017) (123)
- Bowel Ultrasonography in the Management of Crohn's Disease. A Review with Recommendations of an International Panel of Experts (2016) (121)
- Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. (2020) (116)
- Review article: medication non‐adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapies (2008) (115)
- The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management (2019) (115)
- Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease (2010) (113)
- Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. (2020) (113)
- Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy (2018) (108)
- Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease (2013) (108)
- Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease (2008) (107)
- Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease (2011) (102)
- Chronic Exposure to Helicobacter pylori Impairs Dendritic Cell Function and Inhibits Th1 Development (2006) (100)
- Bioactive natural compounds for the treatment of gastrointestinal disorders. (2003) (100)
- A common CTLA4 haplotype associated with coeliac disease (2005) (98)
- Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. (2021) (98)
- A Randomized Trial Comparing High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy for Detection of Colonic Neoplastic Lesions During IBD Surveillance Colonoscopy (2018) (97)
- IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. (2019) (96)
- Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. (2001) (94)
- Modern management of perianal fistulas in Crohn’s disease: future directions (2018) (93)
- Smooth Muscle Hyperplasia/Hypertrophy is the Most Prominent Histological Change in Crohn’s Fibrostenosing Bowel Strictures: A Semiquantitative Analysis by Using a Novel Histological Grading Scheme (2017) (93)
- Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean-a Systematic Review. (2020) (92)
- Effects of mouse and human lipocalin homologues 24p3/lcn2 and neutrophil gelatinase-associated lipocalin on gastrointestinal mucosal integrity and repair. (2006) (87)
- Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases (2011) (86)
- Postoperative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies. (2015) (86)
- Modulation of dendritic cell phenotype and functionin an in vitro model of the intestinal epithelium (2006) (85)
- Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low‐dose azathioprine (2002) (84)
- The Increasing Weight of Crohn's Disease Subjects in Clinical Trials: A Hypothesis-generatings Time-trend Analysis (2013) (83)
- Review article: managing the adverse events caused by anti‐TNF therapy in inflammatory bowel disease (2019) (79)
- Polyunsaturated fatty acids in inflammatory bowel diseases: a reappraisal of effects and therapeutic approaches. (2013) (78)
- Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period (2020) (77)
- Vitamin D and gastrointestinal diseases: inflammatory bowel disease and colorectal cancer (2011) (75)
- Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial (2016) (75)
- Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study (2017) (74)
- Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders (2018) (73)
- Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report (2012) (71)
- Review article: dermatological complications of immunosuppressive and anti‐TNF therapy in inflammatory bowel disease (2013) (71)
- Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs (2019) (70)
- Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn’s Disease Treated With Infliximab [Remicade®] or Conventional Therapy (2016) (69)
- Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. (2011) (68)
- Interaction of malathion, an organophosphorus pesticide with Rhizopus oryzae biomass. (2010) (67)
- Targeted Biopsies Identify Larger Proportions of Patients With Colonic Neoplasia Undergoing High-Definition Colonoscopy, Dye Chromoendoscopy, or Electronic Virtual Chromoendoscopy. (2016) (67)
- Review: Anti-adhesion molecule therapy for inflammatory bowel disease (2010) (66)
- Infliximab use in Crohn's disease: impact on health care resources in the UK (2005) (66)
- Clinic-based Point of Care Transabdominal Ultrasound for Monitoring Crohn's Disease: Impact on Clinical Decision Making. (2015) (64)
- Upper-gastrointestinal bleeding secondary to peptic ulcer disease: incidence and outcomes. (2014) (63)
- Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease (2016) (62)
- The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease (2017) (61)
- Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases (2017) (60)
- Phenotypic features of Crohn's disease associated with failure of medical treatment. (2014) (59)
- Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations (2015) (58)
- Non-Specific Abdominal Pain and Air Pollution: A Novel Association (2012) (57)
- A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease With Bile Acid Pathways (2020) (57)
- Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings (2015) (57)
- Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19 (2020) (56)
- Living with inflammatory bowel disease: A Crohn's and Colitis Canada survey. (2015) (55)
- Cross-Sectional Analysis of Overall Dietary Intake and Mediterranean Dietary Pattern in Patients with Crohn’s Disease (2018) (55)
- Drug-Induced Inflammatory Bowel Disease and IBD-Like Conditions (2013) (54)
- Postoperative complications following colectomy for ulcerative colitis: A validation study (2012) (53)
- Endoscopic and histologic features of sodium phosphate bowel preparation-induced colonic ulceration: case report and review. (2002) (53)
- Ulcerative Colitis Patients With Clostridium difficile are at Increased Risk of Death, Colectomy, and Postoperative Complications: A Population-Based Inception Cohort Study (2016) (52)
- Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges (2020) (52)
- Systematic review: the short‐term and long‐term efficacy of adalimumab following discontinuation of infliximab (2009) (52)
- Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO (Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitis. (2017) (51)
- Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. (2016) (48)
- Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. (2012) (47)
- Dietary n-3 PUFA May Attenuate Experimental Colitis (2018) (46)
- Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England (2009) (46)
- Prevalence and Anatomic Distribution of Serrated and Adenomatous Lesions in Patients with Inflammatory Bowel Disease (2017) (45)
- Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease (2011) (45)
- Inflammatory Bowel Disease Cause-specific Mortality: A Primer for Clinicians (2014) (44)
- O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFN&agr;: UNITI-1 (2016) (43)
- Body composition at the bedside (1997) (43)
- Cellular prion protein is expressed in the human enteric nervous system (2000) (43)
- IBD: In Food We Trust. (2016) (43)
- Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies (2020) (42)
- Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis (2017) (42)
- Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: the IM-UNITI trial. (2021) (42)
- Phase I, double‐blind, randomized, placebo‐controlled, dose‐escalation study of NI‐0401 (a fully human anti‐CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease† (2010) (41)
- Inflammatory Bowel Diseases and Food Additives: To Add Fuel on the Flames! (2019) (41)
- Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management (2019) (40)
- Influences of intestinal bacteria in human inflammatory bowel disease. (2010) (39)
- Liver diseases associated with anti‐tumor necrosis factor‐alpha (TNF‐&agr;) use for inflammatory bowel disease (2011) (39)
- Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome. (2003) (38)
- Ustekinumab for the treatment of Crohn’s disease: can it find its niche? (2016) (38)
- Isotretinoin and intestinal inflammation: what gastroenterologists need to know (2009) (37)
- 5 Crohn's disease: nutrition and nutritional therapy (1998) (37)
- Review article: novel oral‐targeted therapies in inflammatory bowel disease (2018) (37)
- Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease. (2015) (37)
- Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. (2015) (36)
- Review: Optimal use of biologics in the management of Crohn’s disease (2010) (36)
- Advanced endoscopic techniques in the assessment of inflammatory bowel disease: new technology, new era (2018) (36)
- Effect of fish oil enriched enteral diet on inflammatory bowel disease tissues in organ culture: differential effects on ulcerative colitis and Crohn's disease. (2005) (35)
- Beyond white light: optical enhancement in conjunction with magnification colonoscopy for the assessment of mucosal healing in ulcerative colitis (2017) (34)
- Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis (2018) (34)
- Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. (2019) (34)
- Opposing Effects of Smoking in Ulcerative Colitis and Crohn's Disease May Be Explained by Differential Effects on Dendritic Cells (2014) (34)
- Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study (2021) (34)
- Phase 2 Randomized Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Crohn's Disease (2011) (33)
- Perturbation of the Human Microbiome as a Contributor to Inflammatory Bowel Disease (2014) (33)
- An evaluation of the use of serum 7-alpha-hydroxycholestenone as a diagnostic test of bile acid malabsorption causing watery diarrhea. (2011) (33)
- A multimodal (FACILE) classification for optical diagnosis of inflammatory bowel disease associated neoplasia (2018) (33)
- New insights into gastrointestinal and hepatic granulomatous disorders (2011) (33)
- Histopathological Features of Inflammatory Bowel Disease are Associated With Different CD4+ T Cell Subsets in Colonic Mucosal Lamina Propria (2018) (31)
- Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: Results from the CHARM trial (2012) (30)
- Adsorption behavior of lindane on Rhizopus oryzae biomass: physico-chemical studies. (2009) (30)
- Constitutive androstane receptor regulates the intestinal mucosal response to injury (2017) (30)
- Therapeutic value ofalpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab (2003) (30)
- Response assessed by Ultrasonography as Target of Biological Treatment for Crohn's disease: Treat to target in CD using Ultrasonography. (2019) (30)
- Clinical predictors of thiopurine-related adverse events in Crohn's disease. (2015) (29)
- Development and Validation of a Novel Computed-Tomography Enterography Radiomic Approach for Characterization of Intestinal Fibrosis in Crohn's Disease. (2021) (29)
- Small molecule oral targeted therapies in ulcerative colitis. (2020) (29)
- Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease: An International Multicenter Study. (2018) (28)
- Funding a Smoking Cessation Program for Crohn’s Disease: An Economic Evaluation (2015) (28)
- An international multicenter real-life prospective study of electronic chromoendoscopy score PICaSSO in Ulcerative Colitis. (2020) (28)
- Detection of muramyl dipeptide‐sensing pathway defects in patients with Crohn's disease (2006) (28)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial (2011) (28)
- Development and validation of the SIMPLE endoscopic classification of diminutive and small colorectal polyps (2018) (27)
- Advances in novel diagnostic endoscopic imaging techniques in inflammatory bowel disease. (2013) (27)
- Eldelumab [anti-interferon-&ggr;-inducible protein-10 antibody] Induction Therapy for Active Crohn’s Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study (2017) (27)
- Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD. (2021) (27)
- Gut Mucosal Secretion of Interleukin 1β and Interleukin-8 Predicts Relapse in Clinically Inactive Crohn's Disease (2001) (27)
- Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. (2006) (25)
- Gastric fundic gland polyps in south‐east Scotland: Absence of adenomatous polyposis coli gene mutations and a strikingly low prevalence of Helicobacter pylori infection (2002) (25)
- Review: Anti-tumor necrosis factor therapy and influenza: keeping it in perspective (2010) (25)
- Botulinum toxin in the treatment of diffuse esophageal spasm. (2010) (25)
- Clostridium difficile infection worsens the prognosis of ulcerative colitis. (2014) (24)
- Growth factors and trefoil peptides in gastrointestinal health and disease. (2004) (24)
- A diversified dietary pattern is associated with a balanced gut microbial composition of Faecalibacterium and Escherichia/Shigella in patients with Crohn's disease in remission. (2020) (24)
- The Paddington International Virtual Chromoendoscopy Score in ulcerative colitis exhibits very good inter-rater agreement after computerized module training: a multicenter study across academic and community practice (with video). (2018) (24)
- Novel CD8+ T-Cell Subsets Demonstrating Plasticity in Patients with Inflammatory Bowel Disease (2016) (24)
- Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease? (2019) (23)
- Crossover Subsets of CD4+ T Lymphocytes in the Intestinal Lamina Propria of Patients with Crohn’s Disease and Ulcerative Colitis (2017) (23)
- International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease (2021) (23)
- 445 The TOUCHSTONE Study: a Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator (RPC1063) in Moderate to Severe Ulcerative Colitis (2015) (23)
- Gene expression profiling and putative biomarkers of calves 3 months after infection with Mycobacterium avium subspecies paratuberculosis. (2014) (22)
- Advances in the Diagnosis and Management of Inflammatory Bowel Disease: Challenges and Uncertainties (2014) (22)
- Mechanism of intestinal entry of infectious prion protein in the pathogenesis of variant Creutzfeldt-Jakob disease. (2004) (21)
- Histological and molecular diversity and heterogeneity of precancerous lesions associated with inflammatory bowel diseases (2019) (21)
- Infliximab in refractory coeliac disease (2005) (21)
- Transperineal ultrasonography in perianal Crohn disease: A valuable imaging modality. (2015) (20)
- NOD2 activity modulates the phenotype of LPS-stimulated dendritic cells to promote the development of T-helper type 2-like lymphocytes - Possible implications for NOD2-associated Crohn's disease. (2007) (20)
- Beyond TNF, Th1 and Th2 in inflammatory bowel disease (2008) (19)
- Coeliac disease and the risk of infections (2008) (19)
- Infliximab in steroid-resistant ulcerative colitis – a randomised controlled trial. (2003) (19)
- Improving the quality of surveillance colonoscopy in inflammatory bowel disease. (2019) (19)
- Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts (2019) (19)
- Upper gastrointestinal bleeding due to peptic ulcer disease is not associated with air pollution: a case-crossover study (2015) (18)
- 768 A Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Ustekinumab Maintenance Therapy in Moderate - Severe Crohn's Disease Patients: Results From IM-UNITI (2016) (18)
- P273 Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn’s disease: Results from the CELEST study (2018) (18)
- Anti-endomysial Antibody Negative Celiac Disease (2004) (18)
- Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis (2021) (18)
- The Association of Smoking and Surgery in Inflammatory Bowel Disease is Modified by Age at Diagnosis (2016) (18)
- Ulcerative colitis-associated hospitalization costs: a population-based study. (2015) (18)
- Novel Treatment Options for Inflammatory Bowel Disease (2012) (17)
- Crohn's disease in humans and Johne's disease in cattle - linked diseases? (2011) (17)
- Is portal hypertension associated with protein‐losing enteropathy? (2005) (17)
- Normal responses to specific NOD1‐activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease (2006) (17)
- The Positioning of Colectomy in the Treatment of Ulcerative Colitis in the Era of Biologic Therapy (2013) (17)
- Mucosal Healing - How Deep Is Enough? (2016) (17)
- Point of Care Ultrasound Accurately Distinguishes Inflammatory from Noninflammatory Disease in Patients Presenting with Abdominal Pain and Diarrhea (2016) (17)
- Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin. (2006) (16)
- Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients. (2020) (16)
- Degree of Creeping Fat Assessed by CT Enterography is Associated with Intestinal Fibrotic Stricture in Patients with Crohn's Disease: A Potentially Novel Mesenteric Creeping Fat Index. (2021) (16)
- Literature review: impacts of socioeconomic status on the risk of inflammatory bowel disease and its outcomes. (2017) (16)
- OC-043 Long term efficacy and safety of ustekinumab for crohn’s disease: results from im-uniti long-term extension through 2 years (2017) (16)
- Biologic Therapies: Lessons from Multiple Sclerosis (2012) (16)
- Human pancreatic secretory trypsin inhibitor stabilizes intestinal mucosa against noxious agents. (2007) (16)
- Assessment of endoscopic healing by using advanced technologies reflects histologic healing in ulcerative colitis. (2020) (15)
- The NOD2-Smoking Interaction in Crohn's Disease is likely Specific to the 1007 fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study (2017) (15)
- Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland (2010) (15)
- Microscopic Colitis Evolved Into Inflammatory Bowel Diseases Is Characterized by Increased Th1/Tc1 Cells in Colonic Mucosal Lamina Propria (2017) (15)
- Inflammatory Bowel Disease: A Global Disease (2013) (14)
- Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases (2016) (14)
- Phase 2 Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis (2011) (14)
- The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease. (2021) (14)
- What do changes in inflammatory bowel disease management mean for our patients? (2012) (14)
- Ulcerative Colitis and Colon Cancer: Strategies for Cancer Prevention (2002) (14)
- Preventing biliary stent occlusion (1994) (14)
- Talking about life and IBD: A paradigm for improving patient-physician communication. (2009) (13)
- I-scan optical enhancement for the in vivo prediction of diminutive colorectal polyp histology: Results from a prospective three-phased multicentre trial (2018) (13)
- International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases (2021) (13)
- Differences in intestinal humoral immunity between healthy volunteers from UK and Bangladesh (2000) (13)
- 799 – Efficacy of Upadacitinib As an Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis, with Or Without Previous Treatment Failure of Biologic Therapy: Data from the Dose-Ranging Phase 2B Study U-Achieve (2019) (12)
- Intravenous CDP870, a humanized anti-TNF antibody fragment, in patients with active Crohn's disease—An exploratory study (2003) (12)
- Learning the lessons of antitumour necrosis factor therapy-associated psoriasis. (2009) (12)
- Impact of COVID‐19 outbreak on the care of patients with inflammatory bowel disease: A comparison before and after the outbreak in South China (2020) (12)
- The Rising Burden of Inflammatory Bowel Disease in North America from 2015 to 2025: A Predictive Model: 1959 (2015) (12)
- Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters (2021) (12)
- Routine duodenal biopsies to diagnose celiac disease. (2013) (11)
- New tools and approaches for improved management of inflammatory bowel diseases. (2014) (11)
- Diverse Immune Effects of Bovine Colostrum and Benefits in Human Health and Disease (2021) (11)
- Multidisciplinary teams as standard of care in inflammatory bowel disease. (2013) (11)
- P103 - Mesenchymal stem cells administered via novel selective mesenteric artery cannulation for the treatment of severe refractory Crohn's disease (2009) (11)
- Advances in our understanding of the pathogenesis of celiac disease. (2011) (11)
- Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls (2017) (11)
- Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: An Economic Evaluation (2014) (10)
- A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients With Ulcerative Colitis, Using the Pictorial Representation of Illness and Self-measure Tool (2020) (10)
- 624 Final Results of a Randomized Study Comparing High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy Using iSCAN for Detection of Colonic Neoplastic Lesions During IBD Surveillance Colonoscopy (2016) (10)
- Colectomy rates for ulcerative colitis in England 2003‐2016 (2020) (10)
- Randomized controlled study of the prediction of diminutive/small colorectal polyp histology using didactic versus computer‐based self‐learning module in gastroenterology trainees (2019) (9)
- Dietary patterns, food groups and nutrients in Crohn’s disease: associations with gut and systemic inflammation (2021) (9)
- 861 Safety and Efficacy of Pf-00547,659, a Fully Human Anti-MAdCAM Antibody, in Ulcerative Colitis. Results of a First in Human Study (2009) (9)
- Topical therapy in ulcerative colitis: always a bridesmaid but never a bride? (2015) (9)
- Predictors of mortality among patients undergoing colectomy for ischemic colitis: A population-based United States study. (2014) (9)
- Diet and Nutrition in IBD—Progress and Gaps (2019) (9)
- Antibodies to mutated citrullinated vimentin and anti‐cyclic citrullinated peptide antibodies in inflammatory bowel disease and related arthritis (2012) (9)
- Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19 (2021) (8)
- Smoking Is Associated with an Increased Risk for Surgery in Diverticulitis: A Case Control Study (2016) (8)
- The Risk of Inflammatory Bowel Disease in Subjects Presenting With Perianal Abscess: Findings From the THIN Database (2018) (8)
- Tofacitinib in ulcerative colitis. (2016) (8)
- High definition i-SCAN endoscopy with water immersion technique accurately reflects histological severity of celiac disease (2013) (8)
- Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis Republished (2017) (8)
- Ustekinumab: a novel therapeutic option in Crohn’s disease (2016) (8)
- 327 A Randomized Comparison of High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy Using iSCAN for Detection of Colonic Dysplastic Lesions During IBD Surveillance Colonoscopy (2015) (7)
- Granulocyte–monocyte apheresis for the treatment of ulcerative colitis—is this the end of the road? (2009) (7)
- 906 - Efficacy and Safety of Upadacitinib Maintenance Treatment for Moderate to Severe Crohn's Disease: Results from the Celest Study (2018) (7)
- Luminal neutrophil migration in ileoanal pouches studied by whole gut lavage (2000) (7)
- Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis—An Exploratory Study to Define Deep Remission (2021) (7)
- The use of 5-aminosalicylates in Crohn’s disease: a retrospective study using the UK Clinical Practice Research Datalink (2020) (7)
- Amplification of toll-like receptor sensitivity by muramyl dipeptide is impaired in crohn's disease associated NOD2 mutations. (2005) (7)
- A novel method to identify fat malabsorption: the Serum Retinyl Palmitate Test. (2015) (7)
- Nutrient Modulation of Autophagy: Implications for Inflammatory Bowel Diseases (2013) (7)
- Dynamic position change at colonoscopy improves adenoma detection. (2013) (7)
- Can a transition clinic bridge the gap between paediatric and adult inflammatory bowel disease care models? (2020) (7)
- Digital light processing mediated 3D printing of biocomposite bone scaffolds: Physico‐chemical interactions and in‐vitro biocompatibility (2022) (7)
- Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring. (2020) (6)
- Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. (2021) (6)
- Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4 (2000) (6)
- Defining difficult-to-treat inflammatory bowel disease: why and how. (2021) (6)
- OC-057 A PH3 Randomised, Multicenter, Double-Blind, Placebo (PBO)-Controlled Study of Ustekinumab (UST) Maintenance Therapy in Moderate–Severe Crohn’s Disease (CD) PTS: Results from IM-UNITI (2016) (6)
- Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues (2021) (6)
- 865 Phase IIB, Randomized, Placebo-Controlled Evaluation of the Efficacy and Safety of Induction Therapy With Eldelumab (Anti-IP-10 Antibody; BMS-936557) in Patients With Active Ulcerative Colitis (2014) (6)
- RETRACTED: Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (Psc) in Individuals with Inflammatory Bowel Disease. (2016) (6)
- Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs (2019) (6)
- P037 Results of the European Federation of Crohn's and Ulcerative Colitis Associations (Efcca) Patient Survey: Prevalence and Impact on Quality of Life (2007) (6)
- Association between Week Eight Mayo Subscores and Hospitalization Rates in Adalimumab-treated Patients with Ulcerative Colitis from ULTRA 1 and ULTRA 2: 1683 (2013) (6)
- A multicentre development and validation study of a novel lower gastrointestinal bleeding score—The Birmingham Score (2019) (6)
- OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme (2022) (6)
- OC-045 Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate–severe crohn’s disease patients: results from im-uniti maintenance study (2017) (6)
- Corrigendum to “European-evidence-based consensus on the management of ulcerative colitis: Current management” [J Crohns & Colitis 2 (2008) 24–62] (2008) (6)
- Managing the risks of IBD therapy (2009) (6)
- Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions. (2014) (6)
- Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD Clinical Research Activity in the UK (2020) (6)
- What changes in inflammatory bowel disease management can be implemented today? (2012) (5)
- Sa1769 – Worldwide Incidence of Older-Onset Inflammatory Bowel Diseases in the 21ST Century: A Systematic Review of Population-Based Studies (2019) (5)
- Successful infliximab treatment for steroid refractory coeliac disease (2001) (5)
- P300 Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease (2012) (5)
- Novel concepts in inflammatory bowel disease. (2014) (5)
- Sa1743 - Reduced Rates of Crohn's- Related Surgeries, Hospitalizations and Alternate Biologic Initiation with Ustekinumab in the Im-Uniti Study Through 2 Years (2018) (5)
- Dysregulation of IL6/IL6R-STAT3-SOCS3 signaling pathway in IBD-associated colorectal dysplastic lesions as compared to sporadic colorectal adenomas in non-IBD patients. (2020) (5)
- Gut Mucosal Immunity to Tissue Transglutaminase in Untreated Celiac Disease and Other Gastrointestinal Disorders (2002) (5)
- Healthcare Providers Underestimate Patients’ Glucocorticoid Use in Crohn’s Disease (2019) (5)
- Photopolymerizable resin-based 3D printed biomedical composites: Factors affecting resin viscosity (2022) (5)
- P359 Correlation between physician and patient disease assessments in ulcerative colitis: baseline data from the ICONIC study of 1816 patients in 33 countries. (2017) (5)
- Impact of COVID-19 on the Healthcare of Patients With Inflammatory Bowel Disease: A Comparison Between Epicenter vs. Non-epicenter Areas (2020) (5)
- Gut bacteria and ulcerative colitis — A broken tolerance (2000) (4)
- Screening with stable faecal proteins — can they exclude GI pathology? (2000) (4)
- Bioactive fluorcanasite reinforced magnesium alloy based porous bio-nanocomposite bone scaffold with controlled degradation (2022) (4)
- In ̄iximab therapy for Crohn's disease in the presence of chronic hepatitis C infection (4)
- Performance measures in inflammatory bowel disease surveillance colonoscopy: Implementing changes to practice improves performance (2020) (4)
- Investigating iron deficiency anemia without clinical evidence of gastrointestinal blood loss. (2012) (4)
- Abnormal intestinal permeability predicts relapse in patients with inactive Crohn's disease (1998) (4)
- Colorectal polyps in ulcerative colitis and Crohn's colitis. (2015) (4)
- Investigation of bio-degradation behaviour of porous magnesium alloy based bone scaffolds (2021) (4)
- Sa1754 Distinctive Th17 Lymphocyte Plasticity in Intestinal Lamina Propria of IBD Patients Compared With Healthy Controls (2015) (4)
- OP15 A new simplified histology artificial intelligence system for accurate assessment of remission in Ulcerative Colitis (2022) (4)
- A85 EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE–SEVERE CROHN’S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY (2018) (4)
- Extracorporeal photopheresis for the treatment of Crohn's disease. (2015) (4)
- Targeting Integrins and Safety in an Emerging Class of Targeted Oral Therapies: Are We Prepared for Rational and Precision Choices? (2015) (4)
- Is rosiglitazone a promising treatment for ulcerative colitis? (2008) (4)
- Tofacitinib Has Induction Efficacy in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior TNF Inhibitor Therapy: 570 (2016) (4)
- The challenges of medication non-adherence in ulcerative colitis: Practical suggestions to help patients. (2008) (4)
- Safety and Efficacy of Long-Term Treatment with Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Touchstone Extension: 571 (2016) (4)
- Effects of a controlled challenge of chloral hydrate in pneumatosis cystoides coli--further evidence of a causal link? (2000) (4)
- Accuracy of Administrative Data in Identifying Ulcerative Colitis Patients Presenting with Acute Flare and Undergoing Colectomy: 2010 Presidential Poster: 1270 (2010) (4)
- Is an Ounce of Prevention Worth a Pound of Cure: Postoperative Recurrence of Crohn's Disease? (2016) (4)
- Newly recognized non-adenomatous lesions associated with enteric carcinomas in inflammatory bowel disease - Report of six rare and unique cases. (2019) (4)
- P256 Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel iSCAN endoscopic and refined histological gradings (2014) (4)
- Long-Term Efficacy and Safety of Ustekinumab for Crohn’s Disease: Results From Im-Uniti Long-Term Extension Through two Years (2017) (4)
- Sa1787 – The Progression of Inflammatory Bowel Disease Throughout Latin America: A Systematic Review (2019) (4)
- The introduction of the IBD Disk in Poland – a new tool for assessing disability in patients with inflammatory bowel disease (2019) (3)
- P568 Sustained efficacy in patients with ulcerative colitis treated with adalimumab: results from ULTRA 2 (2013) (3)
- Chronic inflammation and other changes are significant components of clinically fibrotic strictures in Crohn’s disease: a histological study of resected strictures clinically characterized as noninflamed (2020) (3)
- Subsequent entry biologics - opportunities and challenges. (2013) (3)
- Persistent Enhancement on Contrast-Enhanced Ultrasound Studies of Severe Crohn's Disease: Stuck Bubbles? (2018) (3)
- OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A’Human MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn’s Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2 (2016) (3)
- P296 Effect of upadacitinib on patient-reported symptoms by the new Ulcerative Colitis Symptoms Questionnaire (UC-SQ) in patients with moderate to severe ulcerative colitis: data from the Phase 2b study U-ACHIEVE (2019) (3)
- Tu1272 Cumulative Incidence of First Intestinal Surgery in Adult and Pediatric Crohn's Disease: A Systematic Review and Meta-Analysis (2012) (3)
- Sa1102 Post-Operative Mortality for the Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Studies (2014) (3)
- Implications of COVID-19 for patients with pre-existing digestive diseases: an update (2021) (3)
- Erratum to: A Diversified Dietary Pattern Is Associated With a Balanced Gut Microbial Composition of Faecalibacterium and Escherichia/Shigella in Patients With Crohn's Disease in Remission. (2020) (3)
- 857 Ozanimod Induces Histological Response and Remission: Results From the TOUCHSTONE Study, a Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis (2016) (3)
- Maintenance therapy with natalizumab improves quality of life in patients with Crohn's disease (2005) (3)
- Response to Biologics in Ibd Patients Assessed by Computerized Image Analysis of Probe Based Confocal Laser Endomicroscopy With Molecular Labeling (2021) (3)
- What is the role of growth factors in IBD? (2008) (3)
- Revisiting the Distinct Histomorphologic Features of Inflammatory Bowel Disease -Associated Neoplastic Precursor Lesions in SCENIC and Post-DALM Era. (2020) (3)
- Safety and Efficacy of Long-term Treatment With Ozanimod: An Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis - TOUCHSTONE Extension 2-Year Follow-up: 595 (2017) (3)
- P319 Inflammatory uncomplicated phenotype at the start of biological therapy predicts best surgery-free outcomes (2012) (3)
- Tu1303 Risk of Surgery Following Diagnosis in Adult and Pediatric Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis (2012) (3)
- Role of Immunosuppressives in Special Situations: Perianal Disease and Postoperative Period (2014) (3)
- Novel irregular vascular pattern features of serrated adenoma detected by high-definition iScan endoscopic technique. (2014) (3)
- Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn’s Disease (2021) (3)
- P552 Association between Week 8 Mayo subscores and hospitalisation rates in adalimumab-treated patients with ulcerative colitis from ULTRA 1 and ULTRA 2 (2014) (3)
- Differential expression of cellular prion protein and its mRNA in the enteric nervous system and non-neuronal elements of the human gut (2000) (3)
- Corrigendum: Surgical Rates for Crohn’s Disease Are Decreasing: A Population-Based Time Trend Analysis and Validation Study (2018) (3)
- OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1 (2016) (3)
- High-definition-iSCAN virtual chromoendoscopy has high sensitivity and specificity for the diagnosis of eosinophilic esophagitis (2017) (2)
- Sa1997 Monitoring Crohns Disease Activity in Children: A Retrospective Comparison of Transabdominal Ultrasound and Ileocolonoscopy (2012) (2)
- Inflammatory bowel disease: Appreciating disability and impact of disease. (2015) (2)
- Post-operative Recurrence of Crohn's Disease: There Is More to It than Meets the Eye. (2016) (2)
- The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. (2016) (2)
- Mo1238 Resected Fibrostenotic Intestine From Crohn's Disease Patients Express Significant TNF in Proliferative Fibroblasts and in Extracellular Matrix (2014) (2)
- A Multicenter Study of Patient Acceptability of the IBD Disk Tool and Patient-Reported Disabilities (2021) (2)
- P139 INSIGHTS INTO PATIENT AND PHYSICIAN COMMUNICATION AND EXPECTATIONS: RESULTS OF A LARGE PAN-EUROPEAN SURVEY OF PHYSICIANS AND THEIR PATIENTS WITH INFLAMMATORY BOWEL DISEASE (2008) (2)
- Clinical outcomes, predictors of prognosis and health economics consequences in IBD patients after discontinuation of the first biological therapy (2020) (2)
- Tests that now deserve to be more widely adopted in IBD clinical practice (2020) (2)
- 493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study (2008) (2)
- Recent advances on injectable nanocomposite hydrogels towards bone tissue rehabilitation (2022) (2)
- P391 Rates of “patient-defined” remission with adalimumab in patients with ulcerative colitis: subanalysis of ULTRA 1 and ULTRA 2 (2013) (2)
- Tu1934 Assessment of Serum C-Reactive Protein, Fecal Lactoferrin, and Fecal Calprotectin in Patients With Moderate-Severely Active Crohns Disease: Results From the IM UNITI Maintenance Study (2016) (2)
- 513 Pregnancy Alters the Pharmacokinetics of Infliximab and Adalimumab in IBD Women (2016) (2)
- Assessment of severity of Clostridium difficile infection. (2011) (2)
- Sa1983 - A Prospective Multicenter “Real Life” International Validation Study of the Picasso Endoscopy Scoring System Againist Histologic Scoring System to Define Mucosal Healing in Ulcerative Colitis (2018) (2)
- DOP099 Five-year safety results from the ENCORE registry: Malignancies in patients with Crohn's disease treated with infliximab, standard therapy, or switched from standard therapy to infliximab (2014) (2)
- A MULTICENTRE VALIDATION STUDY OF A NOVEL LOWER GASTROINTESTINAL BLEEDING (LGIB) SCORE-THE BIRMINGHAM (BHAM) SCORE (2019) (2)
- 812f Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals With Inflammatory Bowel Disease (2016) (2)
- INSIGHTS INTO PATIENT AND PHYSICIAN COMMUNICATION AND EXPECTATIONS: RESULTS OF A LARGE PAN-EUROPEAN SURVEY OF PHYSICIANS AND THEIR PATIENTS WITH INFLAMMATORY BOWEL DISEASE (2008) (2)
- Decreasing Colectomy Rates for Ulcerative Colitis Patients Following Increased Utilization of Immunomodulators and Biologics: A Population-Based Time Trend Study (2011) (2)
- P186 Outcomes of maintenance ustekinumab therapy for Crohn’s disease based on inflammatory burden: A post-hoc analysis of the UNITI trials (2018) (2)
- Optimizing infliximab therapy for inflammatory bowel disease- the tools are getting sharper. (2012) (2)
- Tu1723 – Identification of Risk Factors Associated with Loss of Response to Ustekinumab in Crohn's Disease (2019) (2)
- Long-Term Complications Responsible for Hospital Readmission Following a Colectomy for Ulcerative Colitis: A Population-Based Analysis (2011) (2)
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Study of Ustekinumab, a Human Monoclonal Antibody to Il-12/23p40, in Patients with Moderately to Severely Active Crohnʼs Disease: Results through Week 36 from the CERTIFI Trial: 2011 ACG Presidential Poster: 1227 (2011) (2)
- Venous Thromboembolism in the Hospitalized Ulcerative Colitis Patient (2011) (2)
- W1148 Mesenchymal Stem Cells Administered via Novel Selective Mesenteric Artery Cannulation for the Treatment of Severe Refractory Crohn'sDisease (2009) (2)
- Proteinase 3 (PR3) Autoantibodies as a Serological Marker in Inflammatory Bowel Disease (IBD): 1732 (2013) (2)
- Sa1208 Sustained Efficacy in Patients With Ulcerative Colitis Treated With Adalimumab: Results From ULTRA 2 (2013) (2)
- Effect of Maintenance Ustekinumab on Corticosteroid-Free Clinical Outcomes in Patients with Crohn’s Disease (2017) (2)
- 625 Real Time Histology at Endoscopy - Virtual Electronic Chromoendoscopy and Probe Confocal Laser Endomicroscopy Can Assess Fine Details of Inflammatory Changes in Ulcerative Colitis Patients (2016) (2)
- P112 iSCAN-High definition colonoscopy correlates with white light endoscopy and histology assessment in mucosal healing for ulcerative colitis (2013) (2)
- Long-Term Efficacy of Ustekinumab With and Without Concomitant Immunosuppressants for Crohnʼs Disease: Results From IM-UNITI Long-Term Extension Through 2 Years (2018) (2)
- Management of Crohn’s disease from efficacy, quality of life and health economic perspectives (2003) (2)
- Exaggerated IL-15 and Altered Expression of foxp3+ Cell-Derived Cytokines Contribute to Enhanced Colitis in Nlrp3−/− Mice (2016) (2)
- Sa1875 – Disease-Related Worries and Concerns in Patients with Ulcerative Colitis: 1-Year Data from Iconic (2019) (2)
- OP014 Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extension. (2017) (2)
- Analysing the adhesion strength of Mo-WC-Cu-Si composite coated layer by using the scratch test (2021) (2)
- Maintenance therapy versus episodic therapy with infliximab for Crohn's disease (2004) (2)
- Bioactive fluorcanasite reinforced magnesium alloy-based porous bio-nanocomposite scaffolds with tunable mechanical properties. (2022) (2)
- The Comparative Efficacy of Remission Maintenance Therapy in Crohnʼs Disease: A Bayesian Network Meta-analysis: 1774 (2013) (1)
- Are patient-reported outcome measures the way to go in inflammatory bowel disease? (2014) (1)
- Tu1725 – Characterization of Patients with Delayed Response to Ustekinumab for Crohn's Disease (2019) (1)
- P544 Histological remission following ozanimod treatment is associated with concurrent clinical remission and endoscopic mucosal healing: Results from the TOUCHSTONE study (2018) (1)
- Erratum: Characterization of Inflammatory Bowel Disease With Urinary Metabolic Profiling (2009) (1)
- The Incidence of Inflammatory Bowel Disease Across Time and Geography: A Systematic Review: 1264 (2010) (1)
- Correction: Development and validation of the SIMPLE endoscopic classification of diminutive and small colorectal polyps (2018) (1)
- 131 SAFETY OF USTEKINUMAB IN IBD: A COMPREHENSIVE ANALYSIS OF MAJOR CARDIOVASCULAR EVENTS (MACE) THROUGH 5 YEARS IN CD AND 2 YEARS IN UC (2021) (1)
- Correlation between Physician and Patient Disease Assessments in Ulcerative Colitis: Baseline Data from the Iconic Study of 1816 Patients in 33 Countries (2017) (1)
- Contraindications — Absolute Or Relative? (2007) (1)
- Mo1743 Accuracy and Inter-Observer Agreement for Characterization of Colonic Polyps Using the New Optical Enhancement -iSCAN Closefocus™ Colonoscope (2016) (1)
- Tu1306 Surgical Rates Have Decreased for Emergent Crohn's Disease Resections While Increasing for Elective Resections: A Population-Based Time Trend Study (2012) (1)
- S0645 Efficacy and Safety of Ustekinumab for Crohn's Disease Through 5 Years: Final Results From the IM-UNITI Long-Term Extension (2020) (1)
- S885 Safety of Ustekinumab in Older IBD Patients (≥60 Years): Pooled Safety Analysis Through 5 Years in CD and 2 Years in UC and All Approved Indications (2021) (1)
- Training methods in optical diagnosis and characterization of colorectal polyps: a systematic review and meta-analysis (2021) (1)
- Gut luminal neutrophil migration depends on the anatomical site of crohn's disease (1998) (1)
- 626 Beyond White Light: The First Experience With the New Green-Red-Orange Light Optical Enhancement Magnification Colonoscopy to Define Fine Details of Mucosal Inflammation in Ulcerative Colitis Patients (2016) (1)
- S916 Correlation Between Patient-Reported Outcomes (Pros) and Patient-Reported Disease Activity in Ulcerative Colitis (UC): Findings From the ICONIC Study (2021) (1)
- Sa1778 - Number Needed to Treat to Achieve Clinical Response at Week 8 Along with Response or Remission at Week 52 with Ustekinumab Treatment vs Placebo from the Phase 3 Uniti Crohn's Disease Studies, by Population (2018) (1)
- P281 Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn’s disease studies (2018) (1)
- The classics in perspective (2007) (1)
- An overview of translational research in bone graft biomaterials (2022) (1)
- Estimating benefits of therapy in Crohn's disease in terms of indirect costs. (2011) (1)
- Sa1777 - Combined Clinical and Biological Response (Concomitant Crp and Fecal Calprotectin Reductions) in Induction and Maintenance from the Phase 3 Ustekinumab Crohn's Disease Studies (2018) (1)
- Mo2021 Predicting Polyp Histology - Development and Validation of an International Simple Endoscopic Classification of Small Colorectal Polyps Using the Novel I-Scan Optical Enhancement Colonoscope (2017) (1)
- Ustekinumab is Effective for Inducing Clinical, Endoscopic, and Radiographic Response and Remission in Refractory Moderate-to-Severe Crohn's Disease: A Multicentre Cohort Study (2017) (1)
- Mo1221 Adalimumab Maintains Remission for Up to 4 Years in Patients With Ulcerative Colitis (2014) (1)
- Ulcerative colitis--what can we learn from the Asia-Pacific region? (2014) (1)
- Age at Diagnosis of Crohnʼs Disease May Explain NOD2-Smoking Interactions: 1975 (2015) (1)
- Chronic Diarrhea and Malabsorption (2011) (1)
- S737 Effect of Risankizumab on Patient-Reported Outcomes in Patients With Crohn’s Disease With Inadequate Response or Intolerance to Conventional And/or Biologic Treatments: Results From Phase 3 MOTIVATE and ADVANCE Trials (2021) (1)
- 46 THE FIRST REAL-LIFE MULTICENTRE, INTERNATIONAL, PROSPECTIVE VALIDATION STUDY OF THE ELECTRONIC CHROMOENDOSCOPY SCORING SYSTEM (PICASSO-THE PADDINGTON INTERNATIONAL VIRTUAL CHROMOENDOSCOPY SCORE) AND ITS OUTCOME IN ULCERATIVE COLITIS PATIENTS (2020) (1)
- P-141 Association Between Week 8 Mayo Subscores and Hospitalisation Rates in Adalimumab-treated Patients with Ulcerative Colitis from ULTRA1 and ULTRA2 (2013) (1)
- Measuring Patient Experience in Inflammatory Bowel Disease Care: A Key Component of Continuous Quality Improvement. (2021) (1)
- A Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Results of the Maintenance Period of the TOUCHSTONE Study: 1841 (2015) (1)
- Sa1197 Effects of Vitamin D Supplementation on Intestinal Permeability, Plasma Cathelicidin and Human Beta-Defensin-2 in Crohn's Disease: Results From a Randomised Double-Blind Placebo-Controlled Study (2013) (1)
- OP16 The first virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic remission in Ulcerative Colitis (2022) (1)
- Tu1219 Clinical Outcome of Ulcerative Colitis Patients With Complete Mucosal Healing but With Subtle Abnormalities Detected by Novel iSCAN Endoscopic (2015) (1)
- What's new in … Gastroenterology (2003) (1)
- Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohn's diseaseP-39. (2011) (1)
- Tu1220 To Improve the Evaluation of Eosinophilic Esophagitis by Using High-Definition iSCAN Virtual Chromoendoscopy in Combination With a Refined Histology Scoring System (2015) (1)
- P509 Evaluating clinical practice patterns with inflammatory bowel disease health care assessment questionnaires (POLARIS): a patient- and a physician-reported survey (2013) (1)
- Tu1954 Colonic Confocal Laser Endomicroscopy Findings in Patients With Primary Sclerosing Cholangitis (2013) (1)
- Su1793 - Outcomes of Maintenance Ustekinumab Therapy for Crohn's Disease Based on Inflammatory Burden: A Post-HOC Analysis of the Uniti Trials (2018) (1)
- P672 Number needed to treat to achieve clinical response at week 8 along with response or remission at week 52 with ustekinumab treatment vs. placebo from the phase 3 UNITI Crohn’s disease studies, by population (2018) (1)
- DOP14 Validation of a new OPtical diagnosis Training platform to Improve dysplasia Characterisation in Inflammatory Bowel Disease (OPTIC-IBD): A multicentre randomised controlled study (2022) (1)
- Linking Genotype with Phenotype in Inflammatory Bowel Disease – Will We Ever Have Reagent Standard Patients? (2002) (1)
- Retraction notice to: PS124-Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease [J Hepatol 64 (2016) S199]. (2017) (1)
- Mo1297 Mode of Delivery in Inflammatory Bowel Disease Patients: A Population-Based Study (2013) (1)
- IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: the PROCTRIAL Consensus. (2022) (1)
- Tu2000 Incidence and Mortality of Ischemic Colitis: A Population-Based Study (2013) (1)
- Mo1205 Endoscopic Assessment of Mucosal Healing in Crohn's Disease by Novel iSCAN Endoscopic and Refined Histological Gradings (2015) (1)
- PERFORMANCE MEASURES IN IBD SURVEILLANCE COLONOSCOPY- IMPLEMENTING CHANGES TO PRACTICE IMPROVES PERFORMANCE (2019) (1)
- P.11.8: Inter-Observer Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients with Crohn’s Disease (2017) (1)
- W1218 Experience of Maintenance Infliximab Therapy for Refractory Ulcerative Colitis in England (2008) (1)
- Improvement in Patient Quality of Life during Treatment with Infliximab, Azathioprine, or Combination Infliximab+Azathioprine for Moderate-to-severe Ulcerative Colitis: 1806 (2013) (1)
- A Journey with the Journal (2013) (1)
- An investigation into the viscoelastic response of chemically and physically crosslinked minimally invasive hydrogel scaffolds (2022) (1)
- Intestinal Microparticles and Inflammatory Bowel Diseases: Incidental or Pathogenic? (2014) (1)
- Point-of-care ultrasound accurately distinguishes inflammatory from noninflammatory disease in patients presenting with abdominal pain and diarrhea. (2017) (1)
- Paradoxical Trends in Hospitalization Rates for the Inflammatory Bowel Diseases Between the Western World and Newly Industrialized Countries: A Study of the Organization for Economic Cooperation and Development (OECD): 596 (2017) (1)
- Fr513 INCIDENCE OF INFECTIONS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD AND RELATIONSHIP TO SIGNIFICANT LYMPHOPENIA: RESULTS FROM A POOLED SAFETY ANALYSIS (2021) (1)
- Tu1718 – Immunogenicity of Ustekinumab in Patients with Crohn's Disease: Results from the Im-Uniti Study (2019) (1)
- 31 Patchy Histologic Changes in Symptomatic Celiac Disease Despite Gluten Free Diet Is Accurately Reflected by Confocal Laser Endomicroscopy (2014) (1)
- Effect of Rural Living on the Development of the Inflammatory Bowel Diseases: A Nested Case-control Study: 1252 (2011) (1)
- Mo1208 Timing of Influenza Vaccination Relative to Maintenance Infliximab Infusion in Inflammatory Bowel Disease Patients Does Not Impact Immune Response or Safety of Vaccine (2014) (1)
- Mo1832 Validation of Administrative Data for Capturing Crohn's Disease Patients Requiring Surgical Bowel Resection (2016) (1)
- Su1262 Downregulation of IL-17 Related Cytokines in the Second Trimester of Pregnancy in Women With IBD Supports Pregnancy Driven Immunomodulatory Effects Involving the Th17 Pathway (2015) (1)
- Eosinophilic esophagitis--recognition, diet and drugs. (2012) (1)
- Should we establish standards of care for management of elderly patients with inflammatory bowel disease? (2015) (1)
- Tu1359 High Definition-iSCAN Virtual Chromoendoscopy Has High Sensitivity and Specificity for Histologically Proven Diagnosis of Eosinophilic Esophagitis (2014) (1)
- EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS (2021) (1)
- Clinical quality indicators in inflammatory bowel disease. (2014) (1)
- Su1261 Serum TNF- α Level Changes During Pregnancy Are Associated With Timing of Delivery in IBD Patients (2015) (1)
- P320 The presence of fistulae at baseline does not increase the incidence of adverse events in patients with Crohn's disease in the infliximab ENCORE registry (2014) (0)
- Sa1969 Gene Expression of Matrix Metalloproteinase-3 in Lamina Propria Mononuclear Cells Predicts Response to TNF Inhibitors in Colonic Inflammatory Bowel Disease (2016) (0)
- Tu1071 ENDOSCOPIC CHARACTERISATION OF SMALL/DIMINUTIVE POLYPS BY GASTROENTEROLOGY TRAINEES: A COMPARISON BETWEEN THE NICE AND SIMPLE CLASSIFICATION (2018) (0)
- Sa1164 Treatment of Crohn's Disease With Anti-Tumor Necrosis Factor Decreases Levels of C-Reactive Protein: A Systematic Review and Meta-Analysis (2013) (0)
- A VIRTUAL CHROMOENDOSCOPY ARTIFICIAL INTELLIGENCE SYSTEM TO DETECT ENDOSCOPIC AND HISTOLOGIC REMISSION IN ULCERATIVE COLITIS (2022) (0)
- P715 Achievement and maintenance of endoscopic, histologic, and combined outcomes after extended induction in Week 10 nonresponders of ozanimod: 2-year interim analysis of the True North open-label extension study (2023) (0)
- Su1932 - Despite Surveillance and Increased use of Biologics and Immunosuppressives Colorectal Cancer Detection in IBD Patients Remains Unchanged over the Past 10 Years (2018) (0)
- Efficacy and Safety of Dose Adjustment and Delayed Response to Ustekinumab in Moderate - Severe Crohnʼs Disease Patients: Results from the IM-UNITI Maintenance Study: 2016 ACG Presidential Poster Award: 663 (2016) (0)
- Mo2022 Development and First International Validation and Characterization of Colonic IBD Lesions: Advanced Chromoendoscopy IBD Lesions: Facile Group (2017) (0)
- PTH-025 Predicting polyp histology – development and validation of an international simple endoscopic classification of small colorectal polyps using the novel i-scan optical enhancement colonoscope (2017) (0)
- RAMAN SPECTROSCOPY CAN DIFFERENTIATE MUCOSAL HEALING FROM NON-HEALING IN INFLAMMATORY BOWEL DISEASE (2020) (0)
- Letter: dermatological complications with therapy for inflammatory bowel disease – authors' reply (2014) (0)
- P209 Delayed IBD diagnosis increases risk of requiring biologics in first 4-years - an Inception cohort study (2023) (0)
- P275 Anastomotic technique drives endoscopic recurrence in Postoperative Crohn's Disease: a systematic review and meta-analysis (2023) (0)
- P176 Real-world use of the IBD Disk tool for evaluation of patient-reported disability in the outpatient clinic (2019) (0)
- Novel concepts in in fl ammatory bowel disease (2014) (0)
- Rationally designed biomimetic bone scaffolds with hierarchical porous-architecture: Microstructure and mechanical performance (2023) (0)
- Prevalence and QoL impact of biologics on CD and UC: Results from the EFCCA patient survey: P-0046. (2007) (0)
- Being Canadian with a global dimension. (2010) (0)
- P19 Systemic changes in monoacylglycerols could be an indicator of inflammation in chronic obstructive pulmonary disease (COPD) patients (2022) (0)
- M1071 An Evaluation of the Clinical use of Serum 7 Alpha Hydroxycholestenone as a Test of Bile Acid Malabsorption (2010) (0)
- Mo1715 RAMAN SPECTROSCOPY DEMONSTRATES BIOMOLECULAR CHANGES AND PREDICTS RESPONSE TO BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE (2020) (0)
- Expression of toll-like receptors by intestinal epithelial cells in an in vitro M cell model (2004) (0)
- Sa1797 REAL WORLD USE OF THE IBD DISK TOOL IN UNSELECTED COHORTS OF OUTPATIENTS (2020) (0)
- Sa1049 The Virtual Electronic Chromoendoscopy (Vec) Score in Ulcerative Colitis Exhibits Very Good Inter-Rater Agreement in Scoring Mucosal and Vascular Changes After Computerised Module Training: A Study Across Academic and Community Practice (2017) (0)
- Sa1229 Durable Clinical Remission and Response in Adalimumab-Treated Patients With Ulcerative Colitis (2015) (0)
- Assessment of the early regenerative therapeutic response in graft versus host disease using high definition technology with virtual i-Scan chromoendoscopy (2013) (0)
- Multiple-choice questions in clinical gastroenterology (1998) (0)
- Sa1758 In Vitro Adalimumab Exposure Decreases RORγT Expressing and RORγT/FoxP3 Double Expressing T-Lymphocytes From Peripheral Blood of Crohn's Disease Patients: A Study of Th17 Plasticity in Response to Anti-TNF (2015) (0)
- Su1323 Patients With Crohn's Disease Who Never Smoke Are More Likely to Carry NOD2 Variants: A Case-Only NOD2-Smoking Interaction Study (2015) (0)
- Emotional state should not be used to differentiate IBD from IBS – Authors' reply (2020) (0)
- Su1325 Women With Inflammatory Bowel Disease Are At Higher Risk of Gestational Diabetes: A Novel Finding (2014) (0)
- Innovative Treatments Will Offer a Better Outcome for Patients with IBD (2012) (0)
- Influence of H.pylori — Smoking on recurrent dyspepsia after highly selective vagotomy (2000) (0)
- P-106 Examination of an Alternative Definition for Clinical Remission in UC: Results from TOUCHSTONE, a Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod (2016) (0)
- Elevated interferon-gamma levels during pregnancy are associated with adverse maternofetal outcomes in IBD (2019) (0)
- 845 Patient and Physician Assessment of Disease Burden in Patients With Early UC: 2-Year Data From ICONIC (2019) (0)
- management of the pregnant inflammatory bowel disease patient on antitumour necrosis factor therapy: state of the art and future directions Management of the inflammatory bowel disease patient on antitumour necrosis factor therapy: State of the art and future directions. (2014) (0)
- S734 IBD Patients’ Treatment Preferences Are Heterogeneous, but Largely Affected by the Avoidance of Abdominal Pain and Side Effects (P-POWER IBD Study) (2021) (0)
- Tu1218 Endoscopic Findings of Early GVHD in GI Tract by Novel iSCAN Endoscopy (2015) (0)
- P571 Adalimumab maintains remission for up to 4 years in patients with ulcerative colitis (2014) (0)
- Reply to does cigarette smoke extract really bring out different effects on dendritic cells from ulcerative colitis and Crohn's disease? (2014) (0)
- The in-Vitro Effect of Cigarette Smoke Extract on Monocyte-Derived Dendritic Cell Phenotypes is Different in Crohn's Disease Compared With Ulcerative Colitis Patients (2011) (0)
- Liver OWE-012 NATIONWIDE POPULATION-BASED EVALUATION OF MORTALITY AND CANCER-RISK IN YOUNG PATIENTS WITH ULCERATIVE COLITIS / PRIMARY SCLEROSING CHOLANGITIS (0)
- 129 SAFETY OF USTEKINUMAB IN IBD: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC (2021) (0)
- Mo2093 Histological Chronicity and Subtle Mucosal and Vascular Architectural Changes Can Be Assessed by Novel Endoscopic Techniques in Patients With Ulcerative Colitis (2016) (0)
- T1214 Peripheral Blood from Crohn's Disease Patients Demonstrate Both IL-17 Expressing CD4+ Lymphocytes and IL-17 and Interferon-Gamma Double Expressing CD4+ Lymphocytes (2008) (0)
- Sa1763 1,25-Dihydroxyvitamin D3 Decreases Th1 and Tc1 Lymphocytes From the Peripheral Blood of IBD Patients and Healthy Controls Ex Vivo but Has No Effect on IL-17 or FoxP3 Expression (2015) (0)
- Mo1742 Altered Prevalence of Circulating Novel Tc1, Tc17, Tcreg, and Double-Expressing CD8+ IFN-G+ IL-17+ T Cells in Inflammatory Bowel Disease Patients (2014) (0)
- OXIDATIVE STRESS MANAGEMENT IN TRAINED FEMALES (2016) (0)
- 4.10-P14A 10-year review of abdominal tuberculosis in a single multi-ethnic secondary care population in the UK (2018) (0)
- Relevance of nutriceutical growth factors for the gastrointestinal tract and other organs (2006) (0)
- C-Reactive Protein and Erythrocyte Sedimentation Rate Do Not Correlate With Disease Activity in Pregnant Women With IBD: 1744 (2014) (0)
- P623 Colorectal cancer, colectomy rates and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis: a systematic review and meta-analysis (2019) (0)
- Mo1722 REPRODUCIBILITY OF PICASSO SCORE BY USING NARROW BANDING IMAGES (NBI) TO ASSESS MUCOSAL AND HISTOLOGICAL HEALING IN ULCERATIVE COLITIS (UC) PATIENTS (2020) (0)
- Su1706 A MULTI-CENTRE E COMPARISON OF RISK ASSESSMENT TOOLS IN LOWER GASTROINTESTINAL BLEEDING (LGIB) TO DETERMINE FACTORS PROVIDE THE BEST PREDICTION OF ADVERSE OUTCOMES? (2018) (0)
- A79 FECAL SHORT CHAIN FATTY ACID COMPOSITION IN CROHN’S DISEASE PATIENTS CONSUMING A DIVERSIFIED COMPARED TO NON-DIVERSIFIED DIET (2018) (0)
- Th1/Th2 paradigm-is not enough (2000) (0)
- Sa1862 – Real World Use of the IBD Disk Tool in Unselected Cohorts of Outpatients Shows Encouraging Patient Acceptability and Highlights Fatigue and Joint Pain As Major Contributors to Disability (2019) (0)
- Location and Kudo Pit Pattern Reflect Neoplastic Histology of Lesions Detected at Surveillance Colonoscopy in Inflammatory Bowel Disease (2017) (0)
- Mo1740 OPTICAL ENHANCEMENT AND PROBE CONFOCAL LASER ENDOMICROSCOPY CAN ACCURATELY PREDICT RESPONSE TO BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS (2020) (0)
- Sa1730 – The Histological Healing in Ulcerative Colitis Patients Can Be Predicted by the Combination of Fecal Calprotectin and Endoscopic Healing Assessed by Advanced Optical Enhancement Techniques (2019) (0)
- Time to think about physician wellness in gastroenterology. (2012) (0)
- Su1298 Early Detection of Clostridium difficile Infection Impacts Disease Related Outcomes in Patients With Ulcerative Colitis Patients: A Population-Based Inception Cohort Study (2015) (0)
- Response Rates in the Control Arms of Randomized Controlled Trials: A Systematic Review and Meta-analysis of Trials on Monoclonal Antibodies in Ulcerative Colitis: 1846 (2013) (0)
- Marble waste reinforced composite with tunable physico-mechanical and thermal properties: micromechanical simulation assisted experimental investigation (2023) (0)
- The Interaction Between NOD2 and Smoking Is Specific to the 1007fs SNP of the NOD2 Gene in Crohnʼs Disease: A Systematic Review and Meta-analysis: 1979 (2015) (0)
- P671 An IL23R risk variant is associated with changes in CD4+ T-cell subsets in peripheral blood of Crohn's disease patients (2013) (0)
- Crohn’s disease therapeutic dietary intervention (CD-TDI): study protocol for a randomised controlled trial (2022) (0)
- Impact of COVID-19 outbreak on the care of patients with inflammatory bowel disease: a comparison before and after the outbreak in South China: Impact of COVID-19 on patients with IBD (2020) (0)
- Ischaemic colitis is not just a disease of elderly arteriopaths (1998) (0)
- University of Birmingham Transperineal ultrasonography in perianal Crohn disease (2016) (0)
- A Pooled Safety Analysis from the Ustekinumab Crohnʼs Disease and Psoriatic Diseases Phase 2 and 3 Clinical Trial Programs: 2016 ACG Presidential Poster Award: 662 (2016) (0)
- Tu1037 A RANDOMIZED CONTROLLED STUDY OF THE PREDICTION OF DIMINUTIVE/SMALL POLYP HISTOLOGY USING DIDACTIC VS. COMPUTER BASED SELF-LEARNING MODULE IN GASTROENTEROLOGY TRAINEES (2018) (0)
- Postoperative Mortality for the Inflammatory Bowel Diseases: A Systematic Review and Meta‐analysis of Population‐Based Studies: ACG Fellow Award: 2203 (2014) (0)
- Tu1250 Use of Azathioprine in a Cohort of Crohn's Disease Patients on Anti-TNF Drugs and Related Surgical Outcomes (2012) (0)
- PWE-046 TH17 cells dominate the colonic mucosal immune response in primary sclerosing cholangitis associated colitis (2018) (0)
- Sa1817 – Fibrosis Constitutes Less Than 50% of the Total Volume in a Resected Fibrostenotic Stricture in Crohn's Disease (2019) (0)
- Su1218 Cigarette Smoke Extract Differentially Affects Expression of CD11c in Monocyte-Derived Dendritic Cells in Crohn's Disease Patients With Active Versus Inactive Disease (2015) (0)
- Su2000 – Crohn’s Disease Patients in Remission Consuming a Nondiversified Compared with a Diversified Diet Have Altered Gut Microbiota and Decreased Richness (2019) (0)
- Subject Index Vol. 32, Suppl. 1, 2014 (2014) (0)
- Practice audit in gastroenterology--the route to improving quality and safety. (2011) (0)
- Different Methodologies for Determining Mayo Score in Clinical Studies Can Influence Disease Activity Assessments in Ulcerative Colitis: 1613 (2014) (0)
- ADTU-05 Gut microbial composition in the migrant south-asian IBD population in UK (2018) (0)
- Absence of measles virus (MV) genome in tissue and peripheral blood lymphocytes from patients with Crohn's disease (CD) (1998) (0)
- Su2069 Early Detection and Endomicroscopic Assessment of GvHD in the GI Tract by Confocal Laser Endomicroscopy (2016) (0)
- S1180 Crohn's Disease Is Associated with a Specific Urinary Metabolic Profile (2008) (0)
- University of Birmingham Advanced endoscopic techniques in the assessment of inflammatory bowel disease (2019) (0)
- Correction: PWE-067 Healthcare resource utilisation and QOL in patients with UC by disease severity: iconic baseline data (2018) (0)
- H-pylori infection of DC can lead to inhibition of IL-12 release by DC and INF-gamma production by T-cell (2005) (0)
- Su1203 Lamina Propria T Helper Cell Subsets Distinguish Between Ulcerative Colitis and Crohn's Disease (2015) (0)
- ADWE-01 The prediction of diminutive/small polyp histology using didactic vs computer based training in gastroenterology trainees (2018) (0)
- PWE-067 Healthcare resource utilisation and QOL in patients with UC by disease severity: iconic baseline data (2018) (0)
- Platelets in chronic granulocytic leukemia (1987) (0)
- An era of safety culture. (2012) (0)
- Mo1863 – Extraintestinal Manifestations and Quality of Life in Patients with Ulcerative Colitis: 1-Year Data from Iconic (2019) (0)
- Nutritional and immunological studies in inflammatory bowel disease (1996) (0)
- P282 Despite surveillance and increased use of biologics and immunosuppressives colorectal cancer detection in IBD patients remains unchanged over the past ten years (2018) (0)
- W1154 Non-Invasive Imaging of Transmural Inflammation in Crohn's Disease Using Microbubble Contrast Enhanced Ultrasonography (2009) (0)
- P364 Resected fibrostenotic intestine from Crohn's disease patients express significant TNF in proliferative fibroblasts and in extracellular matrix (2014) (0)
- Sa1267 Fibrostenotic Disease Behavior at the Onset of Biologic Therapy is a Predictor of Poor Outcomes (2012) (0)
- Sa1265 Adalimumab Serum Concentration As a Predictor for Clinical Efficacy in Ulcerative Colitis (2015) (0)
- P273 Colonic confocal laser endomicroscopy findings in patients with primary sclerosing cholangitis (2013) (0)
- Sa2028 Inter-Observer Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease (2016) (0)
- Natalizumab: Another "smart-drug" for Crohn's disease (2003) (0)
- Sa1094 Acute Air Pollution Exposure Is Not Associated With Upper Gastrointestinal Bleeding Secondary to Peptic Ulcer Disease: A Case-Crossover Study (2015) (0)
- IL-12/23 in IBD: Making the Best Use of Available Evidence (2019) (0)
- Fr497 INCIDENCE AND OUTCOMES OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A SYSTEMATIC REVIEW AND META-ANALYSIS (2021) (0)
- Inhibition of NLRP3 Inflammasome Signaling Confers Susceptibility to Intestinal Inflammation Through Dysregulation of IL-15 Expression (2011) (0)
- Sa1752 - Ozanimod Induces Dose-Responsive Histological Improvement with High Agreement with Clinical Remission and Endoscopic Mucosal Healing: Results from the Touchstone Study (2018) (0)
- A106 USTEKINUMAB IS EFFECTIVE FOR MAINTAINING CLINICAL RESPONSE IN REFRACTORY MODERATE-TO-SEVERE CROHN’S DISEASE: A MULTICENTRE COHORT STUDY (2018) (0)
- Acute Severe Ulcerative Colitis (2009) (0)
- Tu1799 – A National, Retrospective, Observational Study on the Use of 5-Aminosalicylates (5-ASA) in Crohn's Disease (CD) (2019) (0)
- Su1914 NOVEL SERUM SOLUBLE MARKERS OF HISTOLOGICAL HEALING IN ULCERATIVE COLITIS (2020) (0)
- S867 Ozanimod for Moderate-to-Severe Ulcerative Colitis: Results From the North American Population During Induction and Maintenance in the Phase 3 True North Study (2021) (0)
- Compliance and Adherence with 5-ASA Therapy for Ulcerative Colitis in Canada: A Retrospective Analysis of a Large Claims Database: 1179 (2010) (0)
- P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial (2021) (0)
- PTH-138 Colorectal cancer, colectomy and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis (2019) (0)
- P335 A prospective multicentre “real-life” international validation study of the PICaSSO endoscopic scoring system against histologic scoring system to define mucosal healing in ulcerative colitis (2018) (0)
- advances in Management of Inflammatory Bowel Disease: The Biological Therapies Era (2005) (0)
- Sa1214 Rates of “Patient-Defined” Remission With Adalimumab in Patients With Ulcerative Colitis: Subanalysis of ULTRA 1 and ULTRA 2 (2013) (0)
- P-137 Safety of Adalimumab in Global Clinical Trials of Ulcerative Colitis Patients (2013) (0)
- University of Birmingham Inflammatory bowel diseases and food additives (2019) (0)
- Su575 DIETARY PREDICTORS OF BIOLOGICAL ACTIVITY IN CROHN'S DISEASE: A RETROSPECTIVE COHORT STUDY (0)
- Mo1735 Regulation of TREM-1 and TREM-2 Protein Expression by Vitamin D in Monocyte-Derived Macrophages From Ulcerative Colitis Patients (2015) (0)
- Su1937 PREDICTORS OF PROGNOSIS AND OUTCOMES AFTER DISCONTINUATION OF FIRST-USE BIOLOGICS IN IBD PATIENTS WITH AT LEAST 24 MONTHS FOLLOW-UP (2020) (0)
- A Randomized Controlled Trial Comparing High-Definition White Light Colonoscopy to I-Scan Enhanced Colonoscopy for Adenoma Detection in a Population at Increased Risk of Colorectal Cancer: A Pilot Study: 1970 (2012) (0)
- Dynamic Management of Crohn’s Disease: Reaching a New Dimension in Patient Care (2020) (0)
- Establishing Normal Parameters of the Small and Large Bowel With Transabominal Ultrasound: A Retrospective Study Comparing Patients With and Without Inflammatory Bowel Disease (2011) (0)
- S1114 IBD Patients Maintained On Azathioprine Have Similar Bone Mineral Density to Patients Maintained On Infliximab with a Low Overall Prevalence of Osteoporosis (2009) (0)
- Su1215 Evaluating Clinical PRactice Patterns With InflammatORy Bowel Disease HeaLTh CArE Assessment QuestIOnnaireS (POLARIS): A Patient- and a Physician-Reported Survey (2013) (0)
- Tu1455: EFFECT OF UPADACITINIB (UPA) TREATMENT ON EXTRAINTESTINAL MANIFESTATIONS (EIMS) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS (UC): RESULTS FROM THE UPA PHASE 3 PROGRAMME (2022) (0)
- A Cost-Utility Analysis of Smoking Cessation Programs for Patients with Crohnʼs Disease: 1738 (2013) (0)
- W1785 Loss of NLRP3 Signaling Results in Altered Dendritic Cells (DC) Population and Impaired Induction of Regulatory T Cells (Treg): Implications for Intestinal Inflammation (2010) (0)
- Efficacy and Safety of Ustekinumab for Crohnʼs Disease: Results From IM-UNITI Long-Term Extension Through 3 Years: Presidential Poster Award (2018) (0)
- OWE-014 Whole transcriptome shotgun sequencing reveals significant upregulation of colonic mucosal immune-mediated anti-microbial mechanisms in psc-uc (2018) (0)
- Predictors of Hospitalization in Patients With Moderately to Severely Active Ulcerative Colitis From ULTRA 1 and ULTRA 2: 1612 (2014) (0)
- Sa1774 Cigarette Smoke Extract Decreases Regulatory T-Cells and Increases IFN-Gamma Secreting T-Cells in Peripheral Blood From Crohn's Disease Compared to Ulcerative Colitis Patients: Differential Smoking Effects on Two Types of Inflammatory Bowel Disease (2013) (0)
- Predictors of Mortality Among Patients Admitted to Hospital for Ischemic Colitis: A Population-Based U.S. Study (2011) (0)
- Is concurrent 5ASA therapy required to maintain azathioprine induced remission in IBD (2000) (0)
- new concepts in irritable Bowel Syndrome – Visceral Hypersensitivity , Inflammation and new therapeutic targets (0)
- Mo1160 Accuracy of Gastroenterologist Performed Point of Care Transabdominal Ultrasound in Detection of Crohn's Disease Activity (2014) (0)
- Adalimumab Therapy is Associated with Improvements in Clinical Laboratory Parameters in Patients with Moderately to Severely Active Crohnʼs Disease: 1243 (2009) (0)
- Editorial Post-operative Recurrence of Crohn's Disease: There Is More to It than Meets the Eye (2016) (0)
- Sa1877 Decreased TGF-ß1 Secretion From Monocyte-Derived Dendritic Cells is Associated With Higher Frequency of IL-17 Secreting FOXP3+ CD4+ T Cells in Peripheral Blood From Inflammatory Bowel Disease Patients (2012) (0)
- Advances in inflammatory bowel disease: are patients taking their medicines? Interview by Paul C. Adams. (2009) (0)
- Ustekinumab Is Effective for the Induction and Maintenance of Response in Crohnʼs Disease: A Multi-center Cohort Study: 641 (2016) (0)
- University of Birmingham Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's Disease (2018) (0)
- Reply to Mendall (2014) (0)
- Cumulative Incidence of Second Major Abdominal Surgery Crohnʼs Disease: A Systematic Review and Meta-analysis of Population-based Studies: 1741 (2013) (0)
- A106 SAFETY OF USTEKINUMAB WITH AND WITHOUT CONCOMITANT CORTICOSTEROIDS OR IMMUNOSUPPRESSANTS IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN’S DISEASE (2018) (0)
- Sa1723 – Mucosal Healing Defined by Advanced Electronic Chromoendoscopy Picasso (Paddington International Virtual Chromoendoscopy Score) and Probe Confocal Laser Endomicroscopy Accurately Predict Histological Healing of Active Inflammation But Not Chronic Changes (2019) (0)
- Sa1123 REGULATORS OF THE GUANYLATE CYCLASE PATHWAY ARE POTENTIAL NOVEL MARKERS OF MUCOSAL HEALING IN IBD (2020) (0)
- Sa1861 Ileal and Colonic Foxp3+ IFNg+ T Cell Prevalence Provides Evidence of Treg-Th1 Plasticity in Humans (2016) (0)
- Fr540 THE PHARMACOKINETICS AND IMMUNOGENICITY OF 5 YEARS OF TREATMENT WITH USTEKINUMAB: RESULTS FROM THE IM-UNITI LONG-TERM EXTENSION (2021) (0)
- A81 POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN’S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3 TRIALS. (2018) (0)
- Tu1733 – Clinical Remission Demonstrated with Oral Ozanimod in the Overall Population and Across Multiple Subgroups of Patients with Moderately to Severely Active Ulcerative Colitis in the Touchstone Trial (2019) (0)
- 1074 The Concordance Between Disease Activity and Prevalence of Th1 Subsets in Patients With Inflammatory Bowel Disease (2016) (0)
- Sa132 TRANSCRIPTOME ANALYSIS IDENTIFIES DYSREGULATED PATHWAYS AND TARGETS FOR THERAPY IN PATIENTS UNDERGOING SURGICAL RESECTION FOR CROHN'S DISEASE (2021) (0)
- Histological Remission is Predictive of Improved Clinical Outcomes in Patients with Ulcerative Colitis: Results from the Touchstone ole (2017) (0)
- A urinary metabolic profile associated with Crohn's disease (2008) (0)
- OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC (2023) (0)
- of Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease (2017) (0)
- PTH-024 The role of probe confocal laser endomicroscopy with image enhanced endoscopy in characterisation and endoscopic resection of dysplastic lesions in inflammatory bowel diseasepatients (2017) (0)
- P056 Gut microbiota characterisation in South Asian IBD patients resident in the UK. (2017) (0)
- RAMAN SPECTROSCOPY DEMONSTRATES BIOMOLECULAR CHANGES AND PREDICTS RESPONSE TO BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE (IBD) (2020) (0)
- Administration of dimethyloxalylglycine (Dmog) as a novel gastrointestinal repair strategy (2007) (0)
- 1076 A Simple, Validated Ultrasonographic Score for the Detection of Inflammation in Established Crohn's Disease (2016) (0)
- Coeliac disease and risk of sepsis. Commentary (2008) (0)
- Tu1525 Sessile Serrated Adenomas Are Common in IBD Surveillance Colonoscopy and Better Detected by Chromoendoscopy and Virtual Chromoendoscopy (2014) (0)
- Tu1710 Up-Regulation of IL-10 and FOXP3 Regulatory T Cells At the Early Subclinical Stage of Experimental Paratuberculosis Infection in Calves (2013) (0)
- Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4. (2000) (0)
- THE FIRST REAL-LIFE MULTICENTRE, PROSPECTIVE VALIDATION STUDY OF THE ELECTRONIC CHROMOENDOSCOPY SCORING SYSTEM (PICASSO-THE PADDINGTON INTERNATIONAL VIRTUAL CHROMOENDOSCOPY SCORE) AND ITS OUTCOME IN ULCERATIVE COLITIS (2020) (0)
- How effective is adalimumab for inducing remission in patients with moderate-to-severe Crohn's disease? (2006) (0)
- P475 Infections and malignancies during anti-TNF therapy in IBD patients affect all age groups – results from a 13-yr real-world retrospective study (2023) (0)
- DOP14 Ultra-high magnification endocytoscopy and molecular markers for defining endoscopic and histologic remission in Ulcerative Colitis (2021) (0)
- P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study (2021) (0)
- Mo1202 Characterization of Anti-Tumor Necrosis Factor Agent-Induced Lupus in Patients With Inflammatory Bowel Disease (2014) (0)
- P773 Extended induction in the True North open-label extension study: clinical outcomes of ~2 years of ozanimod treatment (2023) (0)
- PWE-142 A 10-year review of abdominal tuberculosis experience in a single multi-ethnic hospital population (2017) (0)
- P756 Cumulative adverse events of anti-TNF therapy in IBD patients at a large tertiary centre – a 13-year real-world experience (2023) (0)
- Sa1255 The Comparative Efficacy of Induction of Remission for Mesalamine, Sulfasalazine, and Budesonide for the Treatment of Mild to Moderate Crohn's Disease: A Bayesian Network Meta-Analysis (2015) (0)
- P549 Effect of maintenance Ustekinumab on corticosteroid-free clinical outcomes in patients with Crohn's disease. (2017) (0)
- VALIDATION OF A NEW OPTICAL DIAGNOSIS TRAINING PLATFORM TO IMPROVE DYSPLASIA CHARACTERISATION IN INFLAMMATORY BOWEL DISEASE (OPTIC-IBD): A MULTICENTRE RANDOMISED CONTROLLED STUDY (2022) (0)
- P212 Location and Kudo pit pattern reflect neoplastic histology of lesions detected at surveillance colonoscopy in inflammatory bowel disease. (2017) (0)
- 47 RAMAN SPECTROSCOPY CAN DIFFERENTIATE MUCOSAL HEALING FROM NON-HEALING IN INFLAMMATORY BOWEL DISEASE (2020) (0)
- Tu1310 Treatment of Infliximab or Adalimumab Induces Suppression of Circulating CD45ROHigh CD4+ T-Cells in Crohn's Disease Patients After 4 Weeks of Drug Administration (2015) (0)
- Long-Term Safety of Adalimumab in Clinical Trials in Adult Patients With Crohnʼs Disease or Ulcerative Colitis: 1858 (2015) (0)
- P122 External validation of the Picasso Histological Remission Index (PHRI) to assess endoscopic and histological remission and predict long-term outcome in Ulcerative Colitis: A multicentre prospective study (2023) (0)
- Gut mucosal immunity to tissue transglutaminase (2000) (0)
- P171 PSC/IBD and IBD have similar type and location of colonic lesions, but Dye ChromoEndoscopy (DCE) increases detection rate compared to White Light Endoscopy (WLE) (2022) (0)
- FRI-061-Colorectal cancer, colectomy rates and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis: A systematic review and meta-analysis (2019) (0)
- P275 Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO score (the Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitis. (2017) (0)
- P164 Correlation between physician and patient disease assessments in ulcerative colitis: 2-Year UK data from ICONIC (2021) (0)
- A108 USTEKINUMAB IS EFFECTIVE FOR INDUCING CLINICAL, ENDOSCOPIC, AND RADIOGRAPHIC RESPONSE IN REFRACTORY MODERATE-TO-SEVERE CROHN’S DISEASE: A MULTICENTRE COHORT STUDY (2018) (0)
- P038 Th17 cells dominate the colonic mucosal immune response in primary sclerosing cholangitis associated colitis (2018) (0)
- 76 Surgical Resection Rates for Crohn's Disease Are Decreasing: A Population-Based Time Trend Analysis (2016) (0)
- Ultra-High Magnification Endocytoscopy to Define Deep Endoscopic and Histologic Remission in Ulcerative Colitis (2021) (0)
- Effects of a controlled challenge of chloral hydrate in pneumatosis cystoides coli—further evidence of a causal link? (2000) (0)
- Maintenance of remission in IBD by azathioprine-is neutropenia necessary? (2000) (0)
- Medical Management of Toxic Megacolon (2014) (0)
- OC.02.1 ANASTOMOTIC TECHNIQUE DRIVES ENDOSCOPIC RECURRENCE IN POST-OPERATIVE CROHN'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS (2023) (0)
- P550 Characterisation of hospitalised patients with ulcerative colitis treated with tofacitinib in the OCTAVE clinical programme for up to 7.8 years (2023) (0)
- P-138 Sustained Efficacy in Patients with Ulcerative Colitis Treated with Adalimumab: Results from ULTRA 2 (2013) (0)
- Dietary Intake of Patients with Crohn's Disease in Remission: A Single Center Experience (2017) (0)
- Role of Concomitant Immunosuppression in the Efficacy and Safety of Ustekinumab: Post-Hoc Analyses of UNITI (2018) (0)
- Cross-Sectional Analysis of Overall Dietary Intake and Mediterranean Dietary Pattern in Patient’s with Crohn’s Disease (2018) (0)
- Development and Reliability of the New Endoscopic Virtual Chromoendoscopy Score: The Picasso Score (The Paddington International Virtual Chromoendoscopy Score) in UC (2017) (0)
- Sa1213 Safety of Adalimumab in Global Clinical Trials of Ulcerative Colitis Patients (2013) (0)
- P699 Ustekinumab therapy after biologic failure in patients with Crohn’s Disease – A real-world single centre experience (2023) (0)
- DOP18 Advanced optical diagnosis technology for assessment of endoscopic and histological remission in Ulcerative Colitis: A systematic review and meta-analysis (2022) (0)
- P434 Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn’s disease: Results from induction and maintenance phase 3 trials (2023) (0)
- Mo1729 Differential Effect of Cigarette Smoke Extract Modifies CD103 and CXCR3 Expressions of Monocyte-Derived Dendritic Cells From Crohn's Disease and Ulcerative Colitis Patients (2014) (0)
- P378 Safety of adalimumab in global clinical trials of ulcerative colitis patients (2013) (0)
- Sa1782 Peripheral Blood CD4+ T-Lymphocytes From Crohn's Disease Patients Demonstrate Hyper-Responses to PRO-Inflammatory Cytokines In Vitro by Generating IL-17/FOXP3 Double Expressing Sub-Population (2013) (0)
- Colorectal Neoplasia Surveillance in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: An Economic Evaluation: 2100 (2013) (0)
- P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial (2023) (0)
- Abstracts of the 12th Congress of ECCO – European Crohn’s and Colitis Organisation (2018) (0)
- Reply to Villanacci et al. (2015) (0)
- Lipopolysaccharide increases microparticle uptake in inflamed human colon in vitro (2001) (0)
- University of Birmingham Predictors of mortality among patients undergoing colectomy for ischemic colitis (2016) (0)
- Su1309 The Age Dependent Effect of Smoking on the Risk of Surgery for the Inflammatory Bowel Diseases (2015) (0)
- Ozanimod for moderate-to-severe Ulcerative Colitis (UC): efficacy, safety, and histology results from the induction and maintenance periods of the Phase 3 TRUE NORTH Study (2021) (0)
- PWE-047 Improved patient-reported outcomes with upadacitinib over 52 weeks in patients with moderate-to-severe crohn’s disease (2019) (0)
- 697 Safety of Ustekinumab in Inflammatory Bowel Diseases: Integrated Safety Analysis of Results From Phase 2 and 3 Studies in Crohn's Disease and Ulcerative Colitis (2019) (0)
- Tu1109 The Global Incidence of Appendicitis: A Population-Based North American Cohort Study and Systematic Review (2015) (0)
- DOP01 A multi-centre study to explore the prevalence of Inflammatory Bowel Disease indicators in patients with moderate- to- severe psoriasis: Baseline results from the EPIC study (2022) (0)
- C-Reactive Protein Levels in Moderate to Severe Crohnʼs Disease Patients Decreased Rapidly and Significantly During Adalimumab Therapy: 1197 (2011) (0)
- Relevance of Growth Factors for the Gastrointestinal Tract and Other Organs (2005) (0)
- PTH-102 Association of gut microbiota with mucosal inflammation in ulcerative colitis (2017) (0)
- Mo1258 Peripartum Complications and Assisted Conception in Crohn's Disease Patients Post Bowel Surgery: A Population-Based Study (2013) (0)
- P079 Association of gut microbiota with mucosal inflammation in ulcerative colitis. (2017) (0)
- DOP068 The virtual electronic chromoendoscopy score in ulcerative colitis exhibits very good inter-rater agreement in scoring mucosal and vascular changes after computerised module training: a study across academic and community practice. (2017) (0)
- Sa1200 Predictors of 3-Year Risk of Colectomy Among Hospitalized Patients With Ulcerative Colitis: A Population-Based Study (2015) (0)
- A146 DIETARY INTAKE OF PATIENTS WITH CROHN’S DISEASE IN REMISSION: A CROSS-SECTIONAL STUDY (2018) (0)
- IL-1ß and granulocyte elastase in whole gut lavage fluid predicts relapse in patients with inactive Crohn's disease (1998) (0)
- Mo1227 Clinical Decision Making in Inflammatory Bowel Disease: A Prospective Study to Evaluate Use of Point of Care Ultrasound (2013) (0)
- Sa1777 Novel Regulatory T Cell Population Co-Expressing Ror γT+ or GATA3+ Is Increased in Intestinal Lamina Propria of IBD Patients (2014) (0)
- P127 Optical diagnosis training to improve dysplasia characterisation in inflammatory bowel disease (OPTIC-IBD): a multicentre RCT (2022) (0)
- PTH-027 Location and kudo pit pattern reflect neoplastic histology of lesions detected at surveillance colonoscopy in inflammatory bowel disease (2017) (0)
- PWE-048 The virtual electronic chromoendoscopy score in ulcerative colitis exhibits very good inter-rater agreement in scoring mucosal and vascular changes after computerised module training: a study across academic and community practice (2017) (0)
- Induction Treatment with Anti-TNF Decreases C-Reactive Protein Levels among Crohnʼs Disease Patients: A Systematic Review and Meta-analysis: 1790 (2013) (0)
- Mo1729 Mucosal Gene Expression Patterns From Inflamed Intestine May Distinguish Newly Diagnosed IBD From Established IBD (2015) (0)
- Raman spectroscopy accurately differentiates mucosal healing from non-healing and biochemical changes following biological therapy in inflammatory bowel disease (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Subrata Ghosh?
Subrata Ghosh is affiliated with the following schools:
